StockNews.AI
NLSP
StockNews.AI
215 days

Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS

1. NLS and Kadimastem are finalizing their merger process. 2. Kadimastem has called a meeting for shareholder approval within 14 days. 3. NLS raised $500,000 at a share price of $3.10, 48% above the market. 4. The merger aims to create a robust publicly traded biotech company.

M&A
+0.53%Current Return
VS
+0.64%S&P 500
$1.901/16 09:42 AM EDTEvent Start
$1.9101/17 04:14 PM EDTLatest Updated
14m saved
Insight
Article

FAQ

Why Bullish?

Successful fundraising and merger steps may boost investor confidence in NLSP.

How important is it?

The merger and financial developments are crucial for NLSP's valuation and future operations.

Why Long Term?

Merger completion could enhance NLSP's market position and future growth opportunities.

Related Companies

KDST
Kadimastem Approaches Final Steps for Securing Merger Completion, /PRNewswire/ -- NLS Pharmaceutics Ltd. ("NLS") (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders, and Kadimastem Ltd. ("Kadimastem") (TASE: KDST), a clinical-stage cell therapy company developing and manufacturing "off-the-shelf" allogeneic cell products for the treatment of neurodegenerative diseases and potential cure of diabetes, announces that Kadimastem has issued a notice to convene a special general meeting of Kadimastem's shareholders to approve the merger transaction with NLS. The Central District Court in Israel has approved that this meeting may occur within a reduced time frame of only 14 days from the date of publication of the meeting notice. This meeting is needed to secure Kadimastem's shareholder approval which are critical to completing the merger process. Ronen Twito, Kadimastem's Executive Chairman & CEO and Alexander C. Zwyer NLS's CEO & Executive Board Member This pivotal step follows NLS's recent announcements regarding the successful initial closing of $500,000 from a previously announced $1 million fundraising round, executed at a share price of $3.10—representing a significant 48% increase above the market price at the time of the pricing of the transaction. This financing, along with a previously disclosed $3.2 million investment in October 2024, lays the groundwork for facilitating the proposed merger with NLS, which aims to create a combined Nasdaq-traded biotechnology company with a robust pipeline of advanced therapies. Additionally, NLS has recently filed F-4 Registration Statement on Form F-4 with the U.S. Securities and Exchange Commission (SEC), outlining the details of the proposed merger. Alex Zwyer, Chief Executive Officer of NLS Pharmaceutics, stated, "We are excited about approaching completion of the merger with Kadimastem. This significant step not only demonstrates our commitment to innovation but also holds great potential for delivering enhanced value to our shareholders. Together, we believe that we are poised to redefine the landscape of biotechnology and patient care."Ronen Twito, Executive Chairman and Chief Executive Officer of Kadimastem, commented, "We are pleased to be taking this crucial step toward completing our merger with NLS . We are eager to engage our shareholders in this process as we believe this merger will create a powerful entity in the biotechnology sector, unlocking new opportunities for growth and advancement in innovative therapies."About NLS Pharmaceutics Ltd.NLS is a global development-stage biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders who have unmet medical needs. Headquartered in Switzerland and founded in 2015, NLS is led by an experienced management team with a track record of developing and commercializing product candidates. For more information, please visit www.nlspharma.com.About KadimastemKadimastem is a clinical stage cell therapy company, developing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the company's lead product, is an astrocyte cell therapy in clinical development for the treatment for ALS and in pre-clinical studies for other neurodegenerative indications.IsletRx is the company's treatment for diabetes. IsletRx is comprised of functional pancreatic islet cells producing and releasing insulin and glucagon, intended to treat and potentially cure patients with insulin-dependent diabetes. Kadimastem was founded by Professor Michel Revel, Chief Scientific Officer of Kadimastem and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). Social Media: Social Media: LinkedIn, X, Facebook, InstagramSafe Harbor StatementThis press release contains expressed or implied forward-looking statements pursuant to U.S. Federal securities laws. For example, NLS and Kadimastem are using forward-looking statements when they discuss the expected closing of the transaction and the potential benefits of the transaction to NLS and Kadimastem and their respective shareholders, as well as the expected strategic position of the combined company following the merger, if completed. These forward-looking statements and their implications are based on the current expectations of the management of NLS and Kadimastem and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: risks related to the companies' ability to complete the merger on the proposed terms and schedule, including risks and uncertainties related to the satisfaction of the closing conditions related to the merger agreement and risks and uncertainties related to the failure to timely, or at all, obtain shareholder approvals for the transaction; unexpected costs, charges or expenses resulting from the transaction and potential adverse reactions or changes to business relationships resulting from the announcement or completion of the proposed merger; changes in technology and market requirements; either or both companies may encounter delays or obstacles in launching and/or successfully completing their clinical trials; the companies' products may not be approved by regulatory agencies; their technologies may not be validated as they progress and their methods may not be accepted by the scientific community; either of both of the companies may be unable to retain or attract key employees whose knowledge is essential to the development of their products; unforeseen scientific difficulties may develop with the products being advanced by the companies; their products may wind up being more expensive than anticipated; results in the laboratory may not translate to equally good results in real clinical settings; results of preclinical studies may not correlate with the results of human clinical trials; the companies' patents may not be sufficient; their products may harm recipients; changes in legislation may adversely impact either or both of the companies; inability to timely develop and introduce new technologies, products and applications; and loss of market share and pressure on pricing resulting from competition, which could cause the actual results or performance of candidate products to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, neither Kadimastem nor NLS undertakes any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting NLS is contained under the heading "Risk Factors" in NLS's annual report on Form 20-F for the year ended December 31, 2023, filed with the Securities and Exchange Commission ("SEC"), which is available on the SEC's website, www.sec.gov, and in subsequent filings made by NLS with the SEC, including under the heading "Risk Factors" in NLS's registration statement on Form F-4, filed with the SEC on December 27, 2024.No Offer or Solicitation This communication is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made, except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.Additional Information about the Transaction and Where to Find It In connection with the proposed transaction, NLS has filed a Registration Statement on Form F-4, including a proxy statement/prospectus, with the SEC. NLS may also file other relevant documents with the SEC regarding the proposed transaction. This document is not a substitute for the proxy statement/prospectus or any other document that NLS may file with the SEC. The proxy statement (if and when available) will be mailed or delivered to shareholders of NLS and Kadimastem. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ THE PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS THAT MAY BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THESE DOCUMENTS, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders will be able to obtain free copies of the proxy statement/prospectus (if and when available) and other documents containing important information about NLS and Kadimastem and the proposed transaction, once such documents are filed with the SEC through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by the Company will be available free of charge on NLS's website at www.nlspharma.com.Participants in the Solicitation NLS, Kadimastem, and certain of their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from NLS and Kadimastem shareholders in respect of the proposed transaction. Information about the directors and executive officers of NLS, including a description of their direct or indirect interests, by security holdings or otherwise, is set forth in NLS's Annual Report on Form 20-F for the fiscal year ended December 31, 2023, which was filed with the SEC on May 15, 2024. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed merger when such materials become available. Investors should read the proxy statement/prospectus carefully when it becomes available before making any voting or investment decisions. You may obtain free copies of these documents from NLS Pharmaceutics using the sources indicated above.NLS Contacts:[email protected]www.nlspharma.comKadimastem Contacts:Sarah Bazak, Investors relations[email protected]www.kadimastem.comPhoto: https://mma.prnewswire.com/media/2600028/Ronen_Alexander_CEO.jpgSOURCE Kadimastem Ltd.; NLS Pharmaceutics Ltd. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News